Selective MHC expression in tumours modulates adaptive and innate antitumour responses

Cancer Immunology Immunotherapy

Volumn 48, Issue 7, 1999, Pages 374-381

  Rees, Robert C ^a   Mian, Shahid ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Killer cell inhibitory receptors; Major histocompatibility complex; Natural killer cells; T cells; Tumour escape

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CELL TRANSFORMATION; CONFERENCE PAPER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ESCAPE; VACCINE PRODUCTION;

ANTIGEN PRESENTATION; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 0032842878     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050589     Document Type: Conference Paper

References (81)

1. Andalib AR, Lawry J, Ali SA, Murray AK, Sisley K, Silcocks P, Herlyn M, Rees RC (1997) Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues. Melanoma Res 7:32
2. Benham AM, Neefjes JJ (1997) Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation. J Immunol 159:5896
3. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling (see comments). Nature 393:478
4. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329:512
5. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506
6. Bonal FJ, Pareja E, Martin J, Romero C, Garrido F (1986) Repression of class I H-2K, H-2D antigens on GR9 methylcholanthrene-induced tumour cell clones is related to the level of DNA methylation. J Immunogenet 13:179
7. Bontkes HJ, Walboomers JM, Meijer CJ, Helmerhorst TJ, Stern PL (1998) Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression (letter). Lancet 351:187
8. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC (1993) Three-dimensional structure of the human class II histocompatibility antigen HLA-DRI (see comments). Nature 364:33
9. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF (1993) Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 90:2842
10. Chang SA, Lacaille VG, Guttoh DS, Androlewicz MJ (1996) Binding and transport of melanoma-specific antigenic peptides by the transporter associated with antigen processing. Mol Immunol 33:1165
11. Colonna M, Samaridis J (1995) Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells (see comments). Science 268:405
12. Concha A, Ruiz-Cabello F, Cabrera T, Nogales F, Collado A, Garrido F (1995) Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Eur J Immunogenet 22:299
13. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335
14. D'andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL (1995) Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J Immunol 155:2306
15. D'Urso C, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S (1991) Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2 m gene expression. J Clin Invest 87:284
16. Diederichsen AC, Ostenhom AC, Kronborg O, Fenger C, Jensenius JC, Zeuthen J, Christensen PB, Kristensen T (1998) Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer 79:283
17. Eleuteri AM, Kohanski RA, Cardozo C, Orlowski M (1997) Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity. J Biol Chem 272:11824
18. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290
19. Ferrini S, Cambiaggi A, Meazza R, Sforzini S, Marciano S, Mingari MC, Moretta L (1994) T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur J Immunol 24:2294
20. + anti-tumor T cells requires tumor expression of cell surface MHC class II molecules. Cell Immunol 178:79
21. Frisan T, Levitsky V, Polack A, Masucci MG (1998) Pheno-type-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J Immunol 160:3281
22. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC (1989) Specificity pockets for the side chains of peptide antigens in HLA-Aw68 (see comments). Nature 342:692
23. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89
24. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, Bander NH (1996) Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 155:361
25. Geuze HJ (1998) The role of endosomes and lysosomes in MHC class II functioning. Immunol Today 19:282
26. Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WE, Shepherd L (1991) Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 64:880
27. Hayashi M, Ishibashi T, Tanaka K, Kasahara M (1997) The mouse genes encoding the third pair of beta-type proteasome subunits regulated reciprocally by IFN-gamma: structural comparison, chromosomal localization, and analysis of the promoter. J Immunol 159:2760
28. Ikeda H, Lethe B, Lehmann F, Baren N van, Baurain JF, Smet C de, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199
29. Jiang YZ, Couriel D, Mavroudis DA, Lewalle P, Malkovska V, Hensel NF, Dermime S, Molldrem J, Barrett AJ (1996) Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Immunology 87:481
30. Karre K, Welsh RM (1997) Viral decoy vetoes killer cell (news; comment). Nature 386:446
31. Kerkmann-Tucek A, Banat GA, Cochlovius B, Zoller M (1998) Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination. Int J Cancer 77:114
32. Khanna R, Burrows SR, Moss DJ, Silins SL (1996) Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2 A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 70:5357
33. Knoll MR, Schwab M, Oestreich K, Rumstadt B, Hagmuller E (1997) HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features. J Exp Clin Cancer Res 16:177
34. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC (1996) Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 73:148
35. Kouvidou C, Rontogianni D, Tzardi M, Datseris G, Panayiotides I, Darivianaki K, Karidi E, Delides G, Kanavaros P (1995) Beta 2-microglobulin and HLA-DR expression in relation to the presence of Epstein-Barr virus in nasopharyngeal carcinomas. Pathobiology 63:320
36. Kropshofer H, Vogt AB, Thery C, Armandola EA, Li BC, Moldenhauer G, Amigorena S, Hammerling GJ (1998) A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 17:2971
37. Lanier LL, Phillips JH (1996) Inhibitory MHC class I receptors on NK cells and T cells (see comments). Immunol Today 17:86
38. Lobo PI, Chang MY, Mellins E (1996) Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis. Immunology 88:625
39. Lu Y, Tschickardt ME, Schmidt BJ, Blanck G (1997) IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol 75:325
40. Madiyalakan R, Yang R, Schultes BC, Baum RP, Noujaim AA (1997) OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Hybridoma 16:41
41. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, Moretta A, Long EO (1995) Peptide specificity in the recognition of MHC class I by natural killer cell clones (see comments). Science 267:1016
42. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G (1996) Different effects of interferons, inter-leukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67:826
43. Marx C, Wolkersdorfer GW, Brown JW, Scherbaum WA, Bornstein SR (1996) MHC class II expression - a new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab 81:4488
44. Matsushita K, Takenouchi T, Kobayashi S, Hayashi H, Okuyama K, Ochiai T, Mikata A, Isono K (1996) HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gamma in situ and its association with tumour progression. Br J Cancer 73:644
45. Meazza R, Gaggero A, Neglia F, Basso S, Sforzini S, Pereno R, Azzarone B, Ferrini S (1997) Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides. Eur J Immunol 27:1049
46. Mingari MC, Vitale C, Cambiaggi A, Schiavetti F, Melioli G, Ferrini S, Poggi A (1995) Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int Immunol 7:697
47. + T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA 93:12433
48. Mingari MC, Ponte M, Cantoni C, Vitale C, Schiavetti F, Bertone S, Bellomo R, Cappai AT, Biassoni R (1997) HLA-class I-specific inhibitory receptors in human cytolytic T lymphocytes: molecular characterization, distribution in lymphoid tissues and co-expression by individual T cells. Int Immunol 9:485
49. Mingari MC, Moretta A, Moretta L (1998) Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today 19:153
50. + T cells. Proc Natl Acad Sci USA 95:1172
51. Monaco JJ (1992) A molecular model of MHC class-I-restricted antigen processing. Immunol Today 13:173
52. Mongini C, Sanchez Lockhart M, Waldner CI, Alvarez EM, Gravisaco MJ, Roig MI, Hajos SE (1996) Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection. Br J Cancer 74:258
53. Moretta L, Ciccone E, Moretta A, Hoglund P, Ohlen C, Karre K (1992) Allorecognition by NK cells: nonself or no self? Immunol Today 13:300
54. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L (1996) Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14:619
55. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B (1997) In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7:313
56. Norheim Andersen S, Breivik J, Lovig T, Meling GI, Gaudernack G, Clausen OP, Schjolberg A, Fausa O, Langmark F, Lund E, Rognum TO (1996) K-ras mutations and HLA-DR expression in large bowel adenomas. Br J Cancer 74:99
57. Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G (1995) A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand J Immunol 41:357
58. Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R (1998) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161:2099
59. Phillips JH, Gumperz JE, Parham P, Lanier LL (1995) Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes (see comments). Science 268:403
60. Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58:1486
61. Rees RC, Buckle AM, Gelsthorpe K, James V, Potter CW, Rogers K, Jacob G (1988) Loss of polymorphic A and B locus HLA antigens in colon carcinoma. Br J Cancer 7:374
62. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177:265
63. + T-helper and a T-killer cell (see comments). Nature 393:474
64. Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539
65. Salter J, Maclennan KA, Moore J, Dadian G, Riches PG, Gore ME (1995) The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interteukin-2 in patients with squamous cell carcinoma. J Pathol 76:167
66. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW (1995) Molecular characterization of defective antigen processing in human prostate cancer (see comments). J Natl Cancer Inst 87:280
67. Schoenberger SP, Toes RE, Voort EI van der, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions (see comments). Nature 393:480
68. Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van 't Veer LJ, Kruse-Wolters KM (1991) Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Sem Cancer Biol 2:73
69. Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C (1996) Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56:1756
70. Singal DP, Ye M, Ni J, Snider DP (1996) Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett 50:149
71. Singal DP, Ye M, Qiu X (1996) Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer 68:629
72. Spataro V, Norbury C, Harris AL (1998) The ubiquitin-proteasome pathway in cancer. Br J Cancer 77:448
73. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC (1994) Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215
74. Storkus WJ, Salter RD, Alexander J, Ward FE, Ruiz RE, Cresswell P, Dawson JR (1991) Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. Proc Natl Acad Sci USA 88:5989
75. Thor Straten P, Kirkin AF, Seremet T, Zeuthen J (1997) Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J Cancer 70:582
76. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real FX, Garrido F (1996) Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 47:372
77. Vanky F, Hising C, Sjowall K, Larsson B, Rodriguez L, Orre L, Klein E (1995) Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon gamma and tumour necrosis factor alpha treatment of tumour cells potentiates their interaction with autologous blood lymphocytes. Cancer Immunol Immunother 41:217
78. Vegh Z, Wang P, Vanky F, Klein E (1993) Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res 53:2416
79. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK (1997) An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 76:836
80. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, Bottino C, Moretta L, Moretta A, Long EO (1995) Molecular clones of the p58 NK cell receptor reveal immuno-globulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 2:439
81. Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, Hammerschmidt W (1997) Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 90:2390